Sirius Therapeutics has dosed the first participant with SRSD107 in the P-I, FIH, study on Jan 30, 2024
The P-I trial investigates the safety, tolerability and PK/PD of SRSD107 at single ascending doses and multiple ascending doses among healthy individuals in Australia
SRSD107 is a double-stranded siRNA targeting coagulation factor XI mRNA to inhibit FXI protein expression blocking the intrinsic coagulation pathway thus promoting anticoagulant and anti-thrombotic effects
Ref: Sirius Therapeutics | Image: Sirius Therapeutics
Related News:- GSK Reports the NMPA Acceptance of NDA for Nucala (mepolizumab) to Treat Severe Eosinophilic Asthma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
